Revolution Medicines Reports Breakthrough Phase 3 Results for Pancreatic Cancer Treatment

Revolution Medicines has announced that its daily oral medication, daraxonrasib, successfully met all primary and secondary endpoints in a Phase 3 trial for patients with advanced pancreatic cancer whose disease had progressed on previous treatments. The drug targets RAS mutations, which drive tumor growth and are present in approximately 90% of pancreatic cancer cases. This represents a potential paradigm shift in treatment, moving away from traditional cytotoxic intravenous chemotherapy toward targeted oral therapy for one of the most aggressive forms of cancer. Clinical data revealed a dramatic improvement in patient outcomes. Participants receiving daraxonrasib showed a median survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy. This 6.5-month increase in survival corresponds to a 60% reduction in the risk of death. Revolution Medicines intends to utilize a Commissioner's National Priority Voucher to accelerate the FDA review process, which could grant approval within a matter of months. The company is also currently conducting a separate Phase 3 trial focusing on newly diagnosed patients. Regarding safety, the company reported a manageable safety profile. While a facial rash was identified as a known side effect, clinicians noted that it is generally manageable through temporary drug suspension or antibiotic treatment. Full results are expected to be disclosed at an upcoming medical meeting.